VolitionRx Q3 2026 net loss narrows 30% to $3.8 million; revenue more than doubles to $1.6 million
VNRX•VolitionRx’s third-quarter 2026 net loss narrowed 30% year over year to $3.8 million, while revenue more than doubled to approximately $1.6 million. The company had approximately $2.4 million in cash and cash equivalents at September 30 and prepaid its $7.5 million convertible note balance during the quarter.
1. Quarterly results
VolitionRx reported a third-quarter 2026 net loss of $3.8 million, down 30% year over year. Revenue more than doubled to approximately $1.6 million, primarily on increased recognition of deferred revenue. Cash and cash equivalents totaled approximately $2.4 million at September 30, and the company prepaid its outstanding $7.5 million convertible note balance during the quarter.
2. Commercial updates
VolitionRx said licensing discussions for Capture-Seq are active with several major liquid biopsy and diagnostic companies targeting early cancer detection and residual disease testing. A French reimbursement submission for Nu.Q Lung Cancer is expected this quarter.
